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Introduction
Th   e primary goal of renal replacement therapy (RRT) is 
to compensate for, in part, the loss of renal function and 
associated sequelae. Th  ese include the accumulation of 
nitrogenous waste products, uraemic toxins, electrolyte 
disturbances, metabolic acidosis and volume overload. 
Organ support is much beloved by intensivists and, to an 
extent, deﬁ  nes us, but despite the introduction of convec-
tive therapies, RRT has changed little in the past 50 years. 
Furthermore, the use of current extracorporeal circuits 
does not compensate for other endocrinological and 
metabolic functions of the kidney.
Th   e cause of the acute kidney injury (AKI) necessitating 
RRT is also relevant. Th  e unconditional acceptance of 
terms such as AKI must be considered together with the 
underlying aetiology in order to understand the basic 
pathological processes associated with kidney injury. 
Without an underlying cause, AKI tells us nothing save 
an observed disturbance in conventionally measured 
‘markers’ of function coupled with reduced urine produc-
tion. Clearly, the outcome from AKI in a young patient 
secondary to an interstitial nephritis is very diﬀ  erent 
from that of an elderly diabetic developing AKI following 
systemic infection from a ruptured viscus. It may be that 
the aetiology of the underlying condition is also of great 
import with regard to timing of treatment. In many ways 
this highlights the diﬀ  erences between single organ ‘AKI’ 
and ‘multiorgan AKI’ in that timing of RRT on a renal 
unit may diﬀ  er signiﬁ  cantly from our patients on the ICU 
in terms of both dose delivered and duration of treat  ment.
In ICU patients AKI is often encountered at an early 
stage before traditional measures of renal function are 
deranged. Th  erefore, symptoms may not be as pro-
nounced compared to a patient developing renal failure 
prior to ICU admission. Furthermore, AKI may be 
regarded as a systemic disease, rather than organ failure 
in isolation characterised by a systemic inﬂ  ammatory 
response with concomitant distant organ injury [1]. 
Consequently the indication to start RRT in critically ill 
patients is frequently based on very early signs of AKI, 
such as prolonged oliguria, rather than conventional 
markers of chronic kidney disease.
Numerous articles focus on the topic of initiation of 
RRT in the critically ill and highlight the relative paucity 
of high quality data, as shown in a recent meta-analysis 
with only one published randomised controlled trial 
investi  gating this issue to-date [2]. Th   is narrative review 
is intended as a critical reappraisal of the criteria usually 
applied for initiation of RRT. We wish to outline some of 
the problems associated with determining relative ‘cutoﬀ  ’ 
points for commencing RRT due to the heterogenous 
nature of the ‘triggers’ used for determining need for 
renal replacement. We address both initiation and 
termination of RRT, concentrating on the use of RRT for 
renal support, although mention is made of other 
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© 2011 BioMed Central Ltdindica  tions. A systematic search of the literature was 
performed using the search terms ‘renal replacement 
therapy’, ‘haemoﬁ   ltration’, ‘haemodialysis’, ‘timing’, and 
‘initiation’ and, where possible, the following endpoints 
were extracted: creatinine clearance, glomerular ﬁ  ltration 
rate, increase in serum creatinine, urine output, markers 
of tubular injury and mortality.
Initiation of renal replacement therapy
General considerations
Based on the principle that early goal-directed treatments 
may improve the outcome of critically ill patients, it may 
be argued that a similar approach could be applied to 
RRT. Th   is concept is supported by a hypothesis-
generating meta-analysis suggesting that early initiation 
of RRT in patients with AKI might be associated with 
improved survival [3]. However, this analysis is hampered 
by the usual problems, including predominantly retro-
spective studies and signiﬁ  cantly varied endpoints. As 
recognised from a recent study in chronic kidney disease 
on the initiation of RRT, it appears that no single para-
meter, such as estimated glomerular ﬁ  ltration rate (GFR), 
fulﬁ  ls an adequate criterion for commencing treatment 
[4]. Th   ere  fore, the composite eﬀ  ect of the accumulation 
of poten  tially removable toxins, where non-excreted ﬂ  uid 
can also be regarded as a ‘toxin’, rather than any single 
para  meter seems to deﬁ   ne the trigger point for 
intervention.
Th  e conventional parameters used as indicators of 
renal function (namely urea and creatinine) are relatively 
non-toxic, with their concentration dependent on volume 
of distribution, production rate and tubular reabsorption 
(urea). Th   e volume of distribution for urea or creatinine 
increases signiﬁ  cantly in the volume overloaded critically 
ill patient [5], leading to lower serum concentrations, 
although this may not be the same for other, non-
routinely measured uraemic toxins. Furthermore, the 
‘real’ urea volume of distribution may signiﬁ  cantly sur-
pass estimated total body water in patients with AKI [6]. 
Increased production rates of urea in catabolic patients 
or increased tubular reabsorption in prerenal azotemia 
may lead to high serum concentrations not paralleled by 
other toxic waste products. Consequently, serum levels of 
urea or creatinine may not necessarily reﬂ  ect  the 
concentrations of uremic toxins and an absolute level of 
either urea or creatinine cannot, therefore, be acceptable 
as a deﬁ  ning criterion for ‘early’ versus ‘late’ treatment 
(Figure 1).
Timing of treatment should not be considered in 
isolation but together with the treatment dose applied, 
which, in turn, will determine the time needed until 
control of uraemic waste products is achieved. None of 
the studies on dose of RRT published recently investigate 
tailoring delivered dose. It could be envisaged that 
application of an initial ‘high dose’ followed by a ‘standard 
dose’ may decrease the time period during which homeo-
stasis is severely disturbed. Adopting the current recom-
men  dations regarding RRT, all patients are started with 
the same minimal dose of 25 ml/kg/h; hence, timing of 
treatment may be more relevant if the aim of early goal 
directed therapy in critically ill patients is to minimise 
exposure of the patient to accumulated toxins (Figure 2).
Approximately 20% of patients develop AKI with the 
need for RRT late in their admission and this is associated 
with inferior outcomes [7,8]. However, this criterion (that 
is, time from admission to ICU until start of RRT) is 
deter  mined retrospectively and cannot be applied 
prospec  tively. Conversely, starting RRT very early results 
in adminis  tration of RRT to patients who would recover 
spon  taneously [9] and thus would never have required 
this intervention with its associated risks. Th  ese  include 
the potential loss of trace elements (for example, 
selenium) [10], vitamin depletion (for example, thiamine, 
ascorbic acid), heat loss, nutritional loss (for example, 
amino acids) [11,12] and infection [13]. Potential beneﬁ  ts 
of commencing early therapy must also be weighed 
against potential complications associated with intra-
venous catheter insertion and exposure to relatively high 
dose anticoagulation.
Appraisal of the usual criteria applied in initiating RRT in 
the critically ill
Studies examining timing of RRT in the critically ill have 
to address the criteria used for commencing therapy but 
this is hampered by the lack of any universally accepted 
criteria for initiation. Potential candidates include con-
ven  tional markers of renal dysfunction - urea, creatinine 
and urine output - but other classical indica  tors for RRT, 
Figure 1. Relation of blood urea nitrogen to uremic toxins. 
Blood urea nitrogen (BUN) is infl  uenced by several factors, including 
catabolism, volume of distribution, production rate, and antidiuretic 
hormone release independent of concentration of uremic toxins. 
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acidosis and electrolyte abnorma  lities, cannot be ignored. 
Given this heterogeneity, it is of no surprise that con-
sensus as to when to commence RRT has not been 
reached. In order to try and critically explore this further, 
we discuss each of these parameters independently.
Uraemia, blood urea nitrogen, and serum creatinine
Th  e development of overt uraemic symptoms is an 
obvious indication for initiating RRT but treatment on 
the ICU is rarely, if ever, delayed until full blown uraemia 
develops. However, early signs such as anorexia, nausea, 
vomiting or confusion are non-speciﬁ  c and diﬃ   cult to 
discriminate from the symptoms of other pathologies 
present in these patients. Consequently, progressive 
azotemia is frequently used as an indication to start RRT 
for critically ill patients developing AKI, although at 
present no generally accepted threshold based on a 
deﬁ  ni  tive urea concentration exists.
Th   e concept of prophylactic haemodialysis for the treat-
ment of acute renal failure (ARF) was introduced by 
Teschan and colleagues [14] more than 50  years ago, 
where replacement therapy was started before the 
develop  ment of overt symptoms. Subsequently, data from 
several retrospective case series as well as two further 
trials performed in the 1970s and 1980s led to the recom-
mended threshold of blood urea nitrogen (BUN) for the 
initiation of haemodialysis decreasing to 80 to 100 mg/dl 
(a urea concentration of approximately 29 to 36 mmol/l) 
from the previously quoted 165 to 200 mg/dl (approxi-
mate to 60 to 73  mmol/l) [15-20]. One of the earlier 
studies examining continuous therapies used a BUN 
value of 60 mg/dl (approximate to 22 mmol/l) for deﬁ  ning 
treatment as ‘early’ or ‘late’ [21]. A signiﬁ  cant improve-
ment in survival in the ‘early’ group (average BUN of 
43 mg/dl at initiation (approximate to 15.7 mmol/l)) was 
observed when compared to the ‘late’ group (average 
BUN of 94 mg/dl (approximate to 34 mmol/l)). Another 
retrospective subgroup analysis on 243 ICU patients with 
ARF from the Program to Improve Care in Acute Renal 
Disease (PICARD) study deﬁ   ned early initiation of 
dialysis based on BUN values below the median value of 
76 mg/dl (approximate to 27.7 mmol/l) [22]. Th  e  authors 
found that higher BUN levels on commencing treatment 
(>76 mg/dl, mean 114.8 mg/dl) were associated with an 
increased relative risk for death of 1.85 [22]. Interestingly, 
an increased BUN has been shown to be a ‘biomarker’ for 
increased mortality in several situations, including acute 
heart failure [23], coronary artery disease [24], stroke 
[25], pneumonia [26], bone marrow trans  plantation [27], 
acute pancreatitis [28] and following oesophagectomy [29].
Creatinine is considered a better indicator of GFR and 
was consequently adopted as a parameter for the deﬁ  -
nition of AKI in whatever guise. Indeed, serial measure-
ments of creatinine demonstrating relatively small 
increases is an indicator for increased mortality [30,31]. 
Like urea, creatinine itself is non-toxic and changes in 
serum concentration may occur independently of the 
GFR through changes in volume status, altered produc-
tion, reduced muscle mass or by drug eﬀ   ects on the 
tubular excretion of creatinine. Consequently, although 
changes in serum creatinine have been suggested for 
classifying and staging AKI [32,33], the rate or degree of 
increase in serum creatinine might not adequately reﬂ  ect 
the level of decline of GFR in this setting [34]. Moreover, 
creatinine levels may be decreased in sepsis due to a 
reduction in production rate [35].
So what levels of these parameters are considered 
signiﬁ  cant in our everyday practice? Examination of the 
larger published randomised controlled trials investigat-
ing RRT in critically ill patients with ARF with mortality 
as the end point reveals certain common threads. RRT is 
usually initiated at BUN levels between 50  mg/dl and 
110 mg/dl (approximate to 18 to 40 mmol/l) or a serum 
creatinine between 3.5 and 5 mg/dl (approximate to 300 
to 450 μmol/l), respectively [2,36-41] (Table 1).
Th  erefore, despite the lack of robust trials supporting 
particular levels of these parameters in the initiation of 
RRT in the critically ill, it seems that, as a group, we have 
devised our own! Th  ese reﬂ  ect current clinical practice 
but of course may not be the ideal.
Some studies have demonstrated a ‘paradoxical’ relation-
ship between serum creatinine and outcome in patients 
with AKI and various arguments have centred around 
these ﬁ   ndings, including time between admission and 
commencement of therapy [42]. Th   ese arguments are not 
new, having been discussed in the literature over a decade 
Figure 2. Infl  uence of timing and dosing on exposure to uremic 
toxins. AUCtox is the area under the curve of the respective toxins, 
and early, low dose renal replacement therapy may result in lower 
AUCtox than late, high dose renal replacement therapy. BUN, blood 
urea nitrogen.
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various ways, including reduced muscle mass, reduced 
creatinine production due to sepsis, volume overload and 
malnutrition, although it probably reﬂ  ects the length of 
time elapsed after onset of the condition. Th  erefore, 
patients with the lowest determined serum creatinine at 
the start of RRT have the highest disease burden in terms 
of need for multiorgan support and, as such, the highest 
mortality risk; those commencing RRT later with a higher 
serum creatinine do not. Th  erefore, the higher serum 
creatinine as well as any perceived ‘delay’ in commencing 
RRT reﬂ  ects the fact that these patients are in a more 
favourable group.
Volume overload and oliguria
Volume overload due to salt and water retention fre-
quently complicates AKI, occurring in 30 to 70% of ICU 
patients, and is associated with a greater risk of both 
morbidity and mortality [46-52]. Indeed, patients who 
remain responsive to diuretic treatment demonstrate 
outcome beneﬁ  ts, as do patients exposed to restrictive 
ﬂ  uid management in acute lung injury [53,54]. Although 
diuretics are still frequently employed in order to prevent 
oliguria [55,56], their use has not been translated into any 
perceived beneﬁ  t in AKI [57]. But even if the kidney is 
still (slightly) responsive to furosemide, ultraﬁ  ltration by 
RRT removes ﬂ  uid in an iso-isomolal way, that is, without 
inducing hypernatraemia and alkalosis. Consequently, in 
the presence of refractory severe volume overload, initia-
tion of RRT appears indicated. Moreover, in the intensive 
care setting, initiation of RRT is more fre  quently 
triggered by oliguria expected to result in volume over-
load rather than increases in conventional markers such 
as creatinine or urea [58,59].
A few retrospective studies have investigated early 
initiation of RRT using a more functional approach (com-
paring oliguria to conventional measured criteria). Two 
studies in cardiothoracic patients [60,61] started CRRT 
when urine output was <100 ml over an 8 hour period 
whereas a third study [62] used oliguria for more than 
12  hours as initiation criterion in patients with septic 
shock. All three studies showed signiﬁ  cantly  reduced 
hospital or 30-day mortality in patients where RRT was 
started in the presence of oliguria rather than waiting for 
increases in BUN or serum creatinine. However, the only 
prospective study to date investigating both delivered 
dose and early versus late initiation of treatment found 
no diﬀ  erence between ‘early’ and ‘late’ initiation [2]; a 
caveat is that although well designed, the sample size of 
this study was relatively small.
RIFLE and AKIN criteria
Th  e RIFLE (risk, injury, failure, loss of kidney function, 
and end-stage renal failure) and Acute Kidney Injury 
Network (AKIN) criteria [32,33] were introduced to 
attempt to standardise both the deﬁ  nition and staging of 
AKI. Th  e obvious advantage of these is that they can 
combine increasing serum creatinine and decreasing 
urine output rather than considering just one ‘trigger’ in 
isolation. However, a few retrospective analyses, although 
utilising only creatinine for RIFLE class determination, 
have shown contradictory results [58,63]. If one translates 
the urinary output criteria used in the studies mentioned 
above [60-62] to RIFLE/AKIN classiﬁ  cation, this would 
suggest commencing therapy at either RIFLE Injury or 
AKIN stage II in critically ill patients when both criteria 
(urine output and creatinine) are included. To date, 
however, no trials have investigated the suitability of 
using RIFLE/AKIN criteria for determining the timing of 
RRT.
Electrolyte disturbances
Potassium homeostasis mainly relies on renal excretion 
and hyperkalaemia is thus commonly encountered in 
AKI. Additional factors contributing to hyperkalaemia in 
critical illness include pH-dependant shifts from 
Table 1. Average blood urea nitrogen and serum creatinine and characteristics of patients included in all large 
prospective randomized trials (n > 150) investigating dose of renal replacement therapy
 Number    BUN  Creatinine  Percentage
Study  of patients  APACHE II/III  mg/dl (mmol/l)  mg/dl (μmol/l)  with oliguria
Ronco et al. [37]  425  23  50 (18)  3.6 (318)  100
Mehta et al. [36]  166  24  85 (30)  4.5 (396)  24
Schiffl    et al. [39]  160  87 (III)  90 (32)  5.0 (442)  46
Saudan et al. [38]  206  25  83 (30)  4.8 (428)  37
Tolwani et al. [94]  200  26  76 (27)  4.3 (376)  64
Palevsky et al. [40]  1,124  26  66 (24)  4.1 (362)  78
Bellomo et al. [41]  1,508  102 (III)  64 (23)  3.8 (334)  60
Faulhaber-Walter et al. [95]  157  32  63 (22)  3.1 (273)  73
APACHE, Acute Physiology and Chronic Health Evaluation; BUN, blood urea nitrogen.
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Further  more, rhabdomyolysis, haemolysis and the adverse 
eﬀ   ects of certain drugs (for example, ACE inhibitors) 
may also contribute to hyperkalaemia. Untreated hyper-
kalaemia is fatal, although classical pharmacological 
‘manipulation’ of potassium levels are just that, providing 
transitory improvement through potassium shifts. Th  e 
only eﬀ   ective measures that decrease whole body 
potassium load are diuretic therapy, enteric potassium-
binding resins and RRT. Haemodialysis is the most 
eﬀ   ective way to remove potassium due to the sub-
stantially higher potassium clearance (removing 50 to 
80 mmol potas  sium in a 4 hour session [64]) compared to 
continuous forms of RRT, although continuous veno-
venous haemo  diaﬁ  ltration, where suﬃ   cient total solute 
eﬄ     uent rates are achieved, can be used. A speciﬁ  c 
threshold for initia  tion of RRT in hyperkalaemia cannot 
be recommended because this depends on the acuity of 
serum potassium changes and the observed physiological 
eﬀ  ects on the patient. Usually, RRT is not commenced at 
serum potassium values below 6.5 mmol/l where this is 
the sole indication [65].
Both hyper- and hyponatraemia do occur in AKI, being 
dependent on volume status as well as any remaining 
eﬀ   ective free water clearance by the kidneys. If some 
residual renal function remains, it is rarely necessary to 
start RRT to correct dysnatraemias, although RRT may 
be used as an adjunct to therapy.
While less common, severe hypercalcaemia, hyper-
phos  phataemia, hypermagnesemia and hyperuricaemia 
may be indications for RRT. Severe hypercalcaemia may 
occur in the setting of hyperparathyroidism or malig-
nancy and can lead to crystal nephropathy, tubular 
obstruction and subsequent renal failure. In addition to 
pharmacological treatments including bisphosphonates, 
RRT may be considered as a last resort treatment for 
acute hypercalcaemia [66]. In this case, the use of citrate 
anticoagulation with reduced calcium replacement or 
calcium free dialysis is highly eﬀ  ective.
Metabolic acidosis
Th  e kidney plays a major role in acid-base regulation. 
Renal failure results in increasing levels of plasma organic 
acids and other unmeasured anions through continued 
ﬁ  xed acid production of around 50 to 100 meq H+/day 
[67-69]. RRT plays a major role in acid-base regulation in 
two ways, ﬁ  rstly by removing metabolic acids and secondly 
by the net addition of sodium bicarbonate. High anion gap 
acidoses secondary to poisoning, such as ethylene glycol 
intoxication, are an indication for acute haemodialysis 
with both haemodiaﬁ  ltration as well as extended haemo-
dialysis controlling acidosis in such scenarios [70].
Studies on the use of bicarbonate buﬀ  ered haemo  ﬁ  l-
tration in lactic acidosis, deﬁ  ned by a blood lactate of at 
least 5 mmol/l accompanied either by an arterial pH <7.2 
or need for more than 60 mmol NaHCO3 per hour to 
maintain a stable arterial pH, did demonstrate control of 
acidosis [71]. Th   ese criteria were used in part to initiate 
RRT, although no clear studies exist that deﬁ  ne the exact 
threshold whereby RRT can be started in metabolic 
acidosis with translation into clinical beneﬁ  t or show that 
RRT alters the clinical outcome in the absence of reversal 
of the underlying cause of lactic acidosis. Practically, an 
intractable acidosis is usually considered as an indication 
to commence RRT.
Furthermore, metabolic acidosis increases ventilatory 
demands and high minute volumes to correct pH. By 
correcting metabolic acidosis, RRT may protect the lungs 
against ventilation-induced lung injury.
Biomarkers
Th  e recent literature has seen an expansion in studies 
examining potential ‘biomarkers’ for the early detection of 
AKI. Candidate molecules include Neutrophil gelatinase-
associated lipocalin (NGAL), Kidney injury molecule 
(KIM)-1 and Cystatin C, and the list continues to grow, 
although the quest for the renal ‘troponin’ has been 
hampered by a desire for one biomarker to be seen as 
superior over others. NGAL, a ubiquitous 25-kDa protein 
covalently bound to gelatinase from human neutrophils 
whose expression is increased in the presence of 
inﬂ  ammation and epithelial damage, has received most 
attention in the literature [72,73]. A recent review from 
the NGAL meta-analysis investigator group concludes 
that NGAL appears to be of diagnostic and prognostic 
value for AKI in critically ill patients, albeit in highly 
selected populations [74]. To date, demonstration of 
similarly robust sensitivity and speciﬁ  city in a hetero-
geneous ICU population is lacking. Th  e application of 
biomarkers as indicators for the need for RRT has also 
been examined, with NGAL shown to be a modest 
predic  tor of the need for RRT [75,76]. An alternative 
approach may be the application of biomarkers to 
indicate which patients may not need RRT. Although this 
seems to ﬂ  y in the face of current perceived wisdom, it 
may be that biomarkers such as NGAL could help 
delineate which patients have not had an appreciable 
renal insult. Th  erefore, where biomarker levels are low 
this may translate to lack of an appreciable renal insult. 
Th   is would not be to the total exclusion of other clinical 
markers but may provide additional evidence for renal 
damage or the lack thereof.
Th  e reported conﬂ  icting results do not add credence 
for support of one biomarker convincingly over another 
as yet, but given that the blanket term AKI does not 
specify cause of insult, perhaps the quest for one such 
indicator is naïve. One could propose that AKI is not one 
disease but several under an all encompassing umbrella 
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doomed to failure, particularly when one considers that 
diﬀ  erent biomarkers reﬂ  ect diﬀ  erent pathophysiological 
processes - for example, serum cystatin and glomerular 
ﬁ  ltration, NGAL and inﬂ  ammation, urinary KIM-1 and 
proximal tubular injury - and that tubular damage does 
not always translate into a reduction in clearance.
More research will answer these questions and if 
suitable biomarkers are found, then this may prove to be 
an exciting time in critical care nephrology. One may 
envisage clinical trials aimed at early intervention in 
speciﬁ  c forms of AKI that may alter the course of the 
process: but will they provide a basis for early RRT? Only 
time will tell.
‘Door-to-RRT time’
Prompt dialysis after admission has been shown to 
reduce mortality in certain conditions, such as lepto-
spirosis, resulting in the concept of aiming at a short 
‘door-to-dialysis time’ [77]. Some retrospective analyses 
[7] have employed the time after ICU admission as the 
deﬁ  nition of timing (that is, early versus late) of RRT, 
although this is susceptible to several errors. Firstly, it is 
retrospective, and secondly, AKI may occur on admission 
or later during the ICU stay. Several studies show that 
‘early AKI’ has improved outcomes over ‘late AKI’ [8,9]. It 
may be that early AKI includes those with ‘transitory 
AKI’, which has a signiﬁ   cantly better prognosis [9]. 
Finally, starting RRT in early AKI may include patients 
who would recover spontaneously, and improved out-
come will thus be expected. Indication that very early 
initiation of RRT may be harmful was demonstrated by a 
prospective randomised trial on patients with severe 
sepsis [78]. Delayed weaning from mechanical ventilation 
or vasopressors together with increased mortality was 
observed compared to standard medical treatment.
Non-‘renal’ indications for renal replacement 
therapy
Severe sepsis and septic shock are associated with AKI 
in up to 50% of patients, although classical indicators of 
AKI are often not elevated initially [79]. Consequently, 
other criteria such as prolonged oliguria or severe meta-
bolic acidosis may be suﬃ   cient indication to commence 
RRT [62]. Th  ere remains a theoretical hypothesis that 
removing inﬂ   ammatory mediators associated with 
sepsis could translate into patient beneﬁ  t.  Such 
‘prophylactic’ RRT remains attractive but the only 
prospective randomised study investigating this failed 
to demonstrate any beneﬁ  cial eﬀ  ect of RRT in severe 
sepsis without AKI [80]. As mentioned, early RRT in 
sepsis may even be harmful [78]. Th   us, on the basis of 
current evidence, such a procedure cannot be 
recommended routinely [81].
Th  e use of extracorporeal circuits is also associated 
with signiﬁ  cant blood cooling, which is considered an 
unwanted side eﬀ   ect during routine RRT but may be 
beneﬁ  cial in intractable hyperthermia, such as malignant 
neuroleptic syndrome, malignant hyperthermia and heat 
stroke. Case reports of cooling by extracorporeal circuit 
do exist for all forms of intractable hyperthermia [82]. 
Indeed, a randomised prospective study reports a favour-
able outcome in patients after cardiopulmonary resusci-
ta  tion when applying high volume haemoﬁ  ltration, either 
at 37°C or with cooling [83], but the advent of alternative 
means of cooling, either externally or by adapted central 
venous catheters incorporating a cooled water circuit, 
has superseded the use of extracorporeal circuits.
Dialysis following overdose of dialysable drugs or 
toxins is another indication for RRT. Drugs that can be 
eﬀ   ectively dialysed are characterised by their water 
solubility, low protein binding, low molecular weight 
(<500 Da) and small volume of distribution. Th  us, RRT 
may be considered in cases of overdose or intoxication 
with certain alcohols (for example, methanol, ethylene 
glycol), salicylate, lithium, theophylline or methotrexate 
[84]. Extended dialysis has also been described as being 
successful in paraquat intoxication, although haemo-
perfusion appears more eﬀ  ective [85].
Rhabdomyolysis through whatever cause results in the 
release of myoglobin, leading to AKI through vaso-
constriction, tubular cell damage by oxidant injury and 
tubular obstruction by myoglobin casts. Rhabdomyolysis 
and myoglobinuria are responsible for about 5% of ARF 
in the USA [86] and RRT is typically initiated after the 
failure of more established measures, including alkaline-
ﬂ  uid hydration, mannitol and diuretics. Early initiation of 
RRT for myoglobin removal in severe rhabdomyolysis 
accompanied by acidosis and volume depletion is recom-
mended by some authors [87], although conventional 
membranes have sieving coeﬃ   cients  for  myoglobin 
within the range 0.4 to 0.6. In order to increase eﬃ   ciency 
of myoglobin clearance, the use of super ‘high ﬂ  ux’ 
membranes may be employed [88], although ‘prophy-
lactic’ removal of myoglobin by dialysis has not been 
demonstrated to change the clinical course.
Radiocontrast nephropathy remains a prominent cause 
of hospital-acquired AKI and is still associated with 
signiﬁ   cant mortality [89]. Contrast nephropathy is a 
complex disease, especially in the cardiac patient, where 
it comprises the acute cardiac events compromising 
cardiac function, the negative inotropic eﬀ   ects of the 
contrast medium, pulmonary congestion due to cardiac 
disease, hydration-related ﬂ  uid overload and underlying 
renal insuﬃ   ciency compromising ﬂ  uid removal by the 
kidney. It seems more appropriate, therefore, to talk 
about contrast-associated nephropathy than contrast-
induced nephropathy. RRT before and after contrast 
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severe underlying renal insuﬃ   ciency who may not tolerate 
hydration, may need high contrast volumes or are at risk 
for contrast-induced cardiac decompensation [90,91].
Termination of renal replacement therapy
To date, no clearly deﬁ  ned criteria for the termination of 
RRT have been established. Usual practice is to introduce 
intervals without RRT and await signs of spontaneous 
recovery. Two retrospective trials investigating this found 
urinary output the best predictive parameter for 
cessation of RRT. Th   e Beginning and Ending Supportive 
Th  erapy for the Kidney (BEST kidney) study deﬁ  ned a 
threshold of 450 ml/day as predictive for not requiring 
further RRT [92]. Similarly, an increased risk of 
recommencing dialysis was found for postoperative 
patients with a urinary output <100 ml/8 h [93].
Conclusion
RRT should undoubtedly be initiated in case of life-
threatening conditions such as refractory hyperkalaemia, 
acidosis, ﬂ  uid overload and uremic symptoms, including 
refractory uremic bleeding or pericarditis. However, 
there is a broad consensus that RRT should be initiated - 
if possible - before uremic symptoms develop. Initiation 
should consider the degree of other organ failure, the 
presence of harmful conditions that can be modiﬁ  ed by 
RRT (acidosis, ﬂ   uid overload), the change of serum 
creatinine or urea in relation to ﬂ  uid balance reﬂ  ecting 
renal recovery or not, and the clinical estimate whether 
renal function will recover soon or not (recovery or 
persistence of other organ failure, especially vasopressor-
dependent circulation). Absolute concentrations of urea 
and creatinine are not decisive.
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